Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

What is it about?

As cerebrospinal fluid biomarkers are gaining importance in clinical research and diagnostics of Alzheimer’s disease, there is a need for automated assays that are reliable, afford high throughput, and correlate with other assays. We evaluated the performance of the automated immunoassay system, LUMIPULSE G (FujiRebio), in relation to other immunoassays for measurement of the core Alzheimer’s disease biomarkers, determined intra- and inter-laboratory and longitudinal variability, and established clinical cut-points.

Featured Image